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ABSTRACT 
A series of phenyl-3-(thiophen-2-yl)-4, 5-dihydro-1H-pyrazole-1-carbothioamides (TTa-TTg) 
were synthesized by the ring closure reaction of phenyl-1-(thiophen-2-yl) prop-2-en-1-ones 
with thiosemicarbazide in alcoholic basic medium. All the final derivatives were evaluated for 
their antidepressant and neurotoxicity screening. The structures of the compounds were char-
acterized by IR, 1H NMR, 13C NMR, Mass and elemental analyses. Preclinical evaluation of 
the compounds were ascertained by in silico toxicity, blood-brain barrier and human oral ab-
sorption prediction. In this series, 5-(4-hydroxyphenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-
pyrazole-1 carbothioamide (TTg) reduced immobility time 61.17 and 62.05 % in both force 
swimming and tail suspension test respectively at 10 mg/kg dose level when compared to the 
standard Imipramine without influencing the baseline locomotion. Moreover it was observed 
that the titled scaffold possessing electron withdrawing chlorine atom in the 4th position of ar-
omatic ring of the scaffold also showed good the antidepressant activity. In conclusion, the 
behavioural investigation revealed that thiophene based pyrazolines having a carbothioamide 
tail unit in the N1 position may be therapeutically useful as potential antidepressant medica-
tions. 
 
Keywords: 2-Acetyl thiophene, Pyrazoline, Total polar surface area, Force swimming test,  
Neurotoxicity 
 
 
INTRODUCTION 
In the five membered nitrogen contain-
ing heterocyclic family, pyrazoline could be 
encountered as the most promising scaffold 
for antidepressant activity (Palaska et al., 
2001; Prasad et al., 2005; Ozedemir et al., 
2007; Kalpancikli et al., 2010; Gok et al., 
2010). Recently this nucleus endowed with 
remarkable attention in the inhibition of 
MAO-A, which is considered as the effec-
tive target for the management of depres-
sive disorders (Chimenti et al., 2004; 
Karuppasamy et al., 2010; Nayak et al., 
2013; Salgin-Goksen et al., 2013; Mathew 
et al., 2013a; Kumar et al., 2013). In 1974 
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Parmar et al. identified the therapeutic ben-
efit of pyrazoline nucleus towards MAO-
inhibition and has anticonvulsant action 
(Parmar et al., 1974). In the five membered 
nitrogen containing heterocyclic family, py-
razolines could be considered a valid phar-
macophore for the synthesis of selective 
monoamine oxidase (MAO) inhibitors be-
cause they were developed by the cycliza-
tion of the early hydrazine derivatives such 
as isocarboxazid. The literature survey re-
vealed that the substitutions of pyrazoline 
nucleus preferably at the N1, C3, and C5 po-
sitions showed remarkable effect in the cen-
tral nervous system. 
In the organic perspective view the N-
substituted pyrazolines have been synthe-
sized from the cyclization reaction with 
chalcones and substituted hydrazine deriva-
tives in basic alcoholic medium. Among 
various nitrogen containing heterocycles 
that have been explored for developing 
pharmaceutically important molecules, py-
razolines have attracted a greater attention 
towards the antidepressant action. Consid-
ering that pyrazoline are promising class of 
antidepressants and in the light of afore-
mentioned findings, we aimed to synthesize 
a thiophene based pyrazolines. In the pre-
sent work, it has been planned to attach a 
carbothioamide tail unit in the N1 position 
with a thiophene and substituted phenyl 
system in the 3rd and 5th position of pyrazo-
line template and evaluate their antidepres-
sant action (Figure 1). Preclinical evalua-
tion involves the toxicity prediction and 
pharmacokinetic evaluation of the titled 
compounds by using computational tools. 
Most of the synthesized candidates fail in 
clinical trials because of reasons unrelated 
to potency against intended drug target. 
Pharmacokinetics and toxicity issues are 
blamed for more than half of all failures in 
clinical trials. Many computational predic-
tions are nowadays available to overcome 
such scenario in the drug discovery process. 
In the present study, an attempt has been 
carried out to determine the in silico AD-
METox prediction of the titled synthesized 
compounds to ensure their drug-likeness 
properties. 
 
 
Figure 1: Design of thiophene based pyrazoline 
 
MATERIALS AND METHODS 
Chemistry 
2-Acetyl thiophene was procured from 
Sigma–Aldrich USA. All other chemicals 
and reagents purchased from SD-fine and 
Nice chemicals. Melting points of all the 
synthesized derivatives were determined by 
open-capillary tube method and values were 
uncorrected. IR spectra were recorded on 
Shimadzu FT/IR spectrometer on KBr pel-
lets recorded in cm-1 values.1H NMR and 
13C NMR spectra were recorded on a 
Bruker 400 mhz NMR spectrometer using 
CDCl3 as the solvent. Mass spectra were 
recorded on a JEOL GCmate mass spec-
trometer.  
Synthesis of 3- substituted phenyl-1-
(thiophen-2-yl) prop-2-en-1-ones (Ta-Tg) 
A mixture of 2-acetyl thiophene 
(0.01 mol), aromatic aldehyde (0.01 mol) 
and 40 % aqueous potassium hydroxide 
(15 ml) in ethanol (30 ml) was stirred at 
room temperature for about 2 hr. The re-
sulting product was kept overnight in re-
frigerator. The mixture was poured into 
crushed ice and acidified with 5 % HCl. 
The solid separated was filtered, washed 
with water and recrystallized from ethanol. 
Synthesis of 5- substituted phenyl-3-(thio-
phen-2-yl)-4, 5-dihydro-1H-pyrazole-1-car-
bothioamide (TTa-TTg) 
A mixture of 3-substituted phenyl-1-
(thiophen-2-yl) prop-2-en-1-ones (Ta-Tg) 
(0.01), sodium hydroxide (1 g, 0.025 mol) 
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in ethanol 50 ml and thiosemicarbazide 
(0.012 mol) were magnetically stirred for 
4 hrs. The resulting homogenous mixture 
refluxed for 8-10 hrs in a water bath. The 
products were poured into crushed ice and 
solid mass which was separated out was fil-
tered, washed with water, dried and recrys-
tallized from methanol: benzene (6:4). In 
case of TTf&TTg formation conc. HCl is 
added slightly for the recovery of the prod-
ucts. 
5-phenyl-3-(thiophen-2-yl)-4, 5-dihy-
dro-1H-pyrazole-1-carbothioamide (TTa): 
Dark brown, Yield 70 %, M.p. 120 °C, TLC 
Rf= 0.65(CHCl3/CH3OH,8/2); FT-IR 
(KBr) vmax/cm-1: 3439(NH2), 1573(C=N), 
1471(-CH2-pyrazoline), 1352(C=S), 698(C-
S-C). 1H NMR (CDCl3, 400 MHz, δ ppm): 
3.22(d, 1H, HA), 3.86(d, 1H, HB), 5.55(d, 
1H, HX), 6.05(s, 2H, S=C-NH2), 7.03-
7.47(m, 8H, Ar-H& Th-H). 13C-NMR (400 
MHz, CDCl3, δ ppm): 42.71(CH2, Pyr-C4), 
60.20(CH, Pyr-C5), 125.44-126.78(CH&C, 
Th-C2& Th-C5), 126.85-142.24(CH, Ar-
CH& Th-CH), 144.27(C, Ar-C1), 147.49(C, 
Pyr-C3), 154.95(C=S, CSNH2). MS: m/z 
(M+1) +281. Anal. calcd. for C14H13N3S2: 
C: 58.51, H: 4.56, N: 14.62, S: 22.31. 
Found C: 58.33, H: 4.76, N: 14.52, S: 
22.22. 
5-(4-chlorophenyl)-3-(thiophen-2-yl)-4, 
5-dihydro-1H-pyrazole-1-carboxamide 
(TTb): Cream white, Yield 61 %, 
M.p.180 °C, TLC Rf= 0.61(CHCl3/CH3OH, 
8/2); FT-IR (KBr) vmax/cm-1: FT-IR (KBr) 
vmax/cm-1: 3427(NH2), 1579(C=N), 1469(-
CH2-pyrazoline), 1350(C=S), (Ar-Cl), 713 
(C-S-C). 1H NMR (CDCl3, 400 MHz, δ 
ppm): 3.26(d, 1H, HA), 3.89(d, 1H, HB), 
5.67(d, 1H, HX), 6.02(s, 2H, S=C-NH2), 
7.07-7.49(m, 7H, Ar-H&Th-H). 13C-NMR 
(400 MHz, CDCl3, δ ppm): 41.78(CH2, Pyr-
C4), 60.68(CH, Pyr-C5), 124.43-125.38 
(CH&C, Th-C2& Th-C5), 126.36-141.85 
(CH, Ar-CH& Th-CH), 142.32(C, Ar-C1), 
146.54(C, Pyr-C3), 155.27(C=S, CSNH2). 
MS: m/z (M+2) +321. Anal. calcd. for 
C14H12N3S2Cl: C: 52.25, H: 3.76, N: 11.06, 
S: 19.93. Found C: 52.13, H: 3.58, N: 
11.26, S: 19.23. 
5-(4-methoxyphenyl)-3-(thiophen-2-yl)-
4, 5-dihydro-1H-pyrazole-1-carboxamide 
(TTc): Brown, Yield 67 %, M.p.150 °C, 
TLC Rf= 0.73(CHCl3/CH3OH, 8/2); FT-IR 
(KBr) vmax/cm-1: 3429(NH2), 1602(C=N), 
1510(-CH2-pyrazoline), 1352(C=S), 1250 
(C-O), 712(C-S-C). 1H NMR (CDCl3, 400 
MHz, δ ppm): 3.31(d, 1H, HA), 3.77(s, 3H, 
OCH3), 3.85(d, 1H, HB), 5.47(d, 1H, HX), 
6.02(s, 2H, 2H, S=C-NH2), 6.87-7.60(m, 
7H, Ar-H&Th-H). 13C-NMR (400 MHz, 
CDCl3, δ ppm): 43.64(CH2, Pyr-C4), 55.28 
(CH3, O-CH3), 59.74(CH, Pyr-C5), 114.03-
114.27(CH, Ar-C3&Ar-C5), 126.79-135.07 
(CH, Ar-CH& Th-CH), 147.48(C, Ar-C4), 
154.95(C, Pyr-C3), 159.04(C=S, CSNH2). 
MS: m/z (M+1) +317. Anal. calcd. for 
C15H15N3S2O: C: 56.76, H: 4.76, N: 13.24, 
S: 20.20. Found C: 56.31, H: 4.64, N: 
13.22, S: 20.13. 
5-[4-(dimethylamino) phenyl]-3-(thio-
phen-2-yl)-4, 5-dihydro-1H-pyrazole-1-car-
boxamide (TTd): Greenish black, Yield 
52 %, M.p.129 °C, TLC Rf= 0.84 (CHCl3/ 
CH3OH, 8/2); FT-IR (KBr) vmax /cm-1: 3470 
(NH2), 1593(C=N), 1521(-CH2-pyrazoline), 
1352(C=S), 725(C-S-C). 1H NMR (CDCl3, 
400 MHz, δ ppm): 2.91(s, 6H, (N(CH3)2), 
3.21(d, 1H, HA), 3.79(d, 1H, HB), 5.96(d, 
1H, HX), 6.85(s, 2H, 2H, S=C-NH2), 7.09-
7.83(m, 7H, Ar-H&Th-H). 13C-NMR (400 
MHz, CDCl3, δ ppm): 40.51(CH3, 
N(CH3)2), 43.72(CH2, Pyr-C4), 63.27(CH, 
Pyr-C5), 111.83-112.63(CH, Ar-C3&Ar-
C5), 116.37-132.82(CH, Ar-CH& Th-CH), 
145.00(C, Ar-C4), 150.05(C, Pyr-C3), 
155.00(C=S, CSNH2). MS: m/z (M+1) 
+330. Anal. calcd. for C16H18N4S2: C: 
58.15, H: 5.49, N: 16.95, S: 19.41. Found 
C: 58.32, H: 5.76, N: 16.59, S: 19.42. 
5-(3-nitrophenyl)-3-(thiophen-2-yl)-4, 
5-dihydro-1H-pyrazole-1-carboxamide 
(TTe): Brown, Yield 70 %, M.p.144 °C, 
TLC Rf= 0.82(CHCl3/CH3OH, 8/2); FT-IR 
(KBr) vmax /cm-1: 3361(NH2), 1581(C=N), 
1527(-CH2-pyrazoline), 1350(C=S), 736(C-
S-C). 1H NMR (CDCl3, 400 MHz, δ ppm): 
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3.22(d, 1H, HA), 3.98(d, 1H, HB), 6.15(d, 
1H, HX), 7.10(s, 2H, 2H, S=C-NH2), 7.19-
8.14(m, 7H, Ar-H&Th-H). 13C-NMR (400 
MHz, CDCl3, δ ppm): 43.47(CH2, Pyr-C4), 
62.86(CH, Pyr-C5), 120.84-131.92(CH, Ar-
C3&Ar-C5), 144.27(C, Ar-C3), 147.49(C, 
Pyr-C3), 155.95(C=S, CSNH2). MS: m/z 
(M+1) +332. Anal. calcd. for 
C14H12N4S2O2: C: 50.59, H: 3.64, N: 16.86, 
S: 19.29. Found C: 50.69, H: 3.76, N: 
16.73, S: 19.52. 
5-(2-hydroxyphenyl)-3-(thiophen-2-yl)-
4, 5-dihydro-1H-pyrazole-1 carboxamide 
(TTf): Dark brown, Yield 42 %, 
M.p.140 °C, TLC Rf= 0.73(CHCl3/CH3OH, 
8/2); FT-IR (KBr) vmax /cm-1: 3491(NH2), 
3212(Ar-OH), 1582(C=N), 1496(-CH2-
pyrazoline), 732(C-S-C). 1H NMR (CDCl3, 
400 MHz, δ ppm): 3.34(d, 1H, HA), 3.97(d, 
1H, HB), 5.21(s, 1H, Ar-OH), 5.65(d, 1H, 
HX), 7.01(s, 2H, 2H, S=C-NH2), 7.23-
7.68(m, 7H, Ar-H&Th-H). 13C-NMR (400 
MHz, CDCl3, δ ppm): 43.79(CH2, Pyr-C4), 
61.13(CH, Pyr-C5), 118.23-119.16(CH, Ar-
C1&C3) 127.43-135.68(CH, Ar-CH& Th-
CH), 144.75(C, Ar-C2), 147.68(C, Pyr-C3), 
157.35(C=S, CSNH2). MS: m/z (M+1) 
+281. Anal. calcd. for C14H13N3S2O: C: 
55.42, H: 4.32, N: 13.85, S: 22.14. Found 
C: 55.32, H: 4.18, N: 13.66, S: 22.24. 
5-(4-hydroxyphenyl)-3-(thiophen-2-yl)-
4, 5-dihydro-1H-pyrazole-1-carboxamide 
(TTg): Light brown, Yield 75 %, 
M.p.140 °C, TLC Rf= 0.58(CHCl3/CH3OH, 
8/2); FT-IR (KBr) vmax/cm-1: 3494(NH2), 
3210 (Ar-OH), 1586(C=N), 1495(-CH2-
pyrazoline), 730(C-S-C). 1H NMR (DMSO-
d6, 400 MHz, δ ppm): 1H NMR (CDCl3, 
400 MHz, δ ppm): 3.28(d, 1H, HA), 3.91(d, 
1H, HB),5.27(s,1H,Ar-OH), 5.55(d, 1H, 
HX), 7.06(s, 2H, 2H, S=C-NH2), 7.28-
7.72(m, 7H, Ar-H&Th-H). 13C-NMR (400 
MHz, CDCl3, δ ppm): 43.71(CH2, Pyr-C4), 
60.03(CH, Pyr-C5), 116.03-119.26(CH, Ar-
C3&C5) 127.53-133.66(CH, Ar-CH& Th-
CH), 144.05(C, Ar-C4), 145.69(C, Pyr-C3), 
158.15(C=S, CSNH2). MS: m/z (M+1) 
+281. Anal. calcd. for C14H13N3S2O: C: 
55.42, H: 4.32, N: 13.85, S: 22.14. Found 
C: 55.36, H: 4.16, N: 13.56, S: 22.28. 
 
Preclinical evaluation 
Toxicity prediction of the newly de-
signed scaffold was retrieved from a web-
based application for Organic Chemistry Por-
tal (http://www.organic-chemistry.org/prog) 
(Sander et al., 2009). Blood brain barrier 
prediction was done by utilizing 
(www.cbligand.org/BBB/). The percentage 
of absorption (%ABS) was calculated by 
using topological polar surface area (TPSA) 
of the molecule. Absorption (%ABS) was 
calculated by:  
%ABS = 109-(0.345 × TPSA) (Zaho et al., 
2002). 
 
PHARMACOLOGICAL SCREENING 
The experimental protocol for the 
pharmacological screening on mice were 
done with an Institutional Animal Ethics 
Committee, K.M. College of Pharmacy, 
Madurai, India (Reg no: 661/02/c/ 
CPCSEA). Swiss albino mice (18-25 g) and 
albino rats (80-120 g) of either sex were 
used for the study. The animals were ob-
tained from the K.M. College of Pharmacy, 
Madurai. The animals were housed in colo-
ny cages at an ambient temperature of 
25 ± 2 °C, 12 hr light/dark cycle and 
50 ± 5 % relative humidity with free access 
to food and water ad libitum. Food, but not 
water, was deprived overnight and during 
the experiment. All the experiments were 
carried out during the light period (9.00-
16.00 hrs). Each group consisted of six an-
imals. 
 
Antidepressant activity 
Forced swim test (FST) 
The development of immobility when 
the rats are placed in an inescapable cylin-
der filled with water reflects the cessation 
of persistent escape-directed behaviour. The 
cylindrical container (diameter 10 cm, 
height 25 cm) was filled to a 19-cm depth 
with water at (25 ± 1 °C). The duration of 
immobility during the 6 min test was 
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scored. Each rat was judged to be immobile 
when it ceased struggling and remained 
floating motionless in the water, making 
only those movements necessary to keep its 
head above water. (Porsolt et al., 1977) 
Tail suspension test (TST) 
The total duration of immobility by the 
Tail suspension test was measured accord-
ing to the previously described method 
(Setru et al., 1985). Rats were isolated both 
acoustically and visually and suspended 50 
cm above the floor by adhesive tape placed 
approximately 1 cm from the tip of the tail. 
Immobility time was observed during a 
6 min test for animals of all groups. Rats 
were considered to be immobile when they 
hung passively and were completely mo-
tionless. The percentage change relative to 
control was calculated by the following 
equation. 
% Change of immobility = 
[(test/control) ×100) - 100] 
Evaluation of motor coordination activity  
The motor coordination and perfor-
mance of each mouse was evaluated 30 min 
after i.p. administration of (TTa-TTg) 
(10 mg/kg) and standard diazepam 
(4 mg/kg) in a rota-rod apparatus. This 
equipment has a bar 2.5 cm in diameter and 
divided into six parts, and it is placed at a 
height of 50 cm, rotating at 20 rpm. Laten-
cy to fall from the rotating bar was regis-
tered. 
 
RESULTS AND DISCUSSION 
Chemistry 
The intermediate of thiophene based 
heteroaryl chalcones have been synthesized 
by Claisen–Schmidt condensation between 
2-acetyl thiophene and appropriate phenyl 
and substituted phenyl aldehydes in pres-
ence of alcoholic basic medium (Satyana-
rayana et al., 2013; Mathew et al., 2013b). 
The formation of pyrazoline nucleus in-
volves the nucleophilic addition of the ami-
no group of thiosemicarbazide to the keto 
group of thiophene chalcone afford imine 
linkage. It was followed by the cyclisation 
with β-carbon unit of 1-(2-thienyl)-3-aryl-
2-propen-1-one (Aboul-Enein et al., 2012). 
The synthetic route involved in the for-
mation of titled compounds were outlined 
in Figure 2. The IR spectra of TTe showed 
the disappearance of C=O band and appear-
ance of a new band at 1581 cm-1 recom-
mended the formation of C=N. This func-
tional group transformation indicates the 
ring closure. The band at 3361 and 
1527 cm-1 corresponds to the NH2 and CH2 
of pyrazoline nucleus respectively. In pro-
ton NMR, pyrazoline ring protons (HA and 
HB) showed at around 3.22 and 3.98 ppm as 
a doublet and also vicinal methine proton 
HX showed triplet/doublet at about 6.15 
ppm due to vicinal coupling with the two 
magnetically non-equivalent protons of the 
methylene group HA and HB. NH2 protons 
of the carbamoyl group were seen at 7.10 
ppm in the case of TTe. In 13C-NMR spec-
tra the peaks for pyrazoline at C3, C4 and C5 
are in the range of 145.69-154.95 ppm, 
43.79-40.51 ppm and  ppm 
respectively. In Mass spectra of TTe, the 
fragment peaks which corresponds to loss 
of H2S, O and NO2 molecular ion are con-
sistent with the postulated structure. The 
splitting of an oxygen atom from the TTe 
derivative showed a peak of 316 which cor-
respond to the molecular formula of 
C14H12N4OS2 gave a full agreement of the 
formation of 5-(3-nitrophenyl)-3- (thio-
phen-2-yl)-4, 5-dihydro-1H-pyrazole-1-car-
bothioamide.The details of the mass frag-
mentation pattern of TTe is shown in Fig-
ure 3. 
 
Preclinical evaluation 
The toxicity assessment of all the final 
synthesized derivatives were shown in Ta-
ble 1. It is quite interesting to see that all 
the compounds were free from all type of 
toxicity issues mentioned in the software 
package except TTe which exhibited a me-
dium risk mutagenic effect. Pharmacokinet-
ic profile of the synthesized molecules were 
shown in Table 2. The positive values of 
the candidates towards the blood brain bar-
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rier indicated their ability in acting in the 
CNS. The unsubstituted and the presence of 
lipophilic halogen or electron donating 
groups in the phenyl nucleus of titled deriv-
atives showed a TPSA below 51. The low 
score of TPSA suggested that these mole-
cule preferentially act as hydrophobic in na-
ture and can easily transport through the 
blood brain barrier. It can be observed that  
Figure 2: Synthetic route of the titled deriva-
tives 
 
Figure 3: Mass fragmentation pattern of TTe 
all the titled thiophene analogues exhibited 
a good %ABS ranging from 78.83 to 
94.63 %.  
 
Antidepressant activity 
The antidepressant activities for the 
synthesized derivatives (TTa-TTg) were 
carried by Force swimming test (FST) and 
Tail suspension test (TST) in rat at dose of 
10 mg/kg in comparison with the standard 
drug imipramine (15 mg/kg). Antidepres-
sant activity was determined as mean im-
mobility time in seconds and data has been 
presented as mean ± S.E.M in Table 3. The 
results suggested that all the compounds 
showed good antidepressant potential in the 
experimental animal models. In the series 
of thiophene based pyrazoline carbthioam-
ide derivatives, 5-(4-hydroxyphenyl)-3-
(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1 
carbothioamide (TTg) reduced immobility 
time 61.17 and 62.05 % in both FST and 
TST respectively at 10 mg/kg dose level 
when compared to the standard Imipramine. 
The preliminary SAR of newly synthesized 
carboxamides suggested that the com-
pounds possessing electron-releasing 
groups such as hydroxy either in the ortho 
or para and withdrawing chlorine in the 4th 
position of aromatic rings of the scaffold 
showed good the antidepressant activity. 
Neurotoxicity of the compounds were ac-
cessed by rotarod test. Interestingly, all the 
compounds in the series have passed neuro-
toxicity test. 
Table 1: Toxicity prediction of titled derivatives (TTa-TTg) 
Compound 
code 
Mutagenic Tumerogenic Irritant Reproductive 
effect 
TTa 
TTb 
TTc 
TTd 
TTe 
TTf 
TTg 
No 
No 
No 
No 
Medium 
No 
No 
No 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
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Table 2: Physicochemical properties of titled derivatives (TTa-TTg) 
Compound 
code ClogP
a TPSAb 
Blood brain bar-
rier prediction %ABS 
TTa 
TTb 
TTc 
TTd 
TTe 
TTf 
TTg 
2.36 
3.06 
2.75 
2.51 
2.10 
1.64 
1.69 
41.63 
41.63 
50.86 
44.86 
87.45 
61.85 
61.85 
0.074 
0.051 
0.047 
0.013 
0.094 
0.005 
0.014 
94.63 
94.63 
91.45 
93.52 
78.83 
87.66 
87.66 
a: Calculated by ChemDraw Ultra 8.0 
b: Calculated by Molinspration tool 
 
Table 3: In vivo antidepressant activity and neurotoxicity of the (TTa-TTg) on wistar albino rats 
Compound 
codea 
Forced swim test Tail suspension test 
Rotarod 
testb 
Duration of 
immobility 
 (in sec) 
% change 
relative to 
control 
Duration of 
immobility  
(in sec) 
% change 
relative to 
control 
TTa 
TTb 
TTc 
TTd 
TTe 
TSf 
TSg 
Control 
Imipramine 
(15mg/Kg i.p.) 
63.75 ± 18** 
63.12 ± 2.55** 
67.87 ± 2.72** 
66.42 ± 2.43** 
69.35 ± 2.83** 
61.34 ± 3.25** 
58.34 ± 3.15** 
155.60 ± 9.42 
52.43 ± 2.45*** 
-59.02 
-59.29 
-56.38 
-57.31 
-55.43 
-60.57 
-62.50 
- 
-66.30 
65.11 ± 2.32** 
64.13 ± 2.74** 
74.62 ± 2.02** 
72.68 ± 2.35** 
72.44 ± 2.72** 
68.44 ± 2.43** 
65.54 ± 2.41** 
171.21 ± 10.32 
56.32 ± 2.37***
-61.97 
-62.54 
-56.41 
-57.54 
-57.68 
-60.02 
-61.71 
- 
-67.10 
2/6 
1/6 
1/6 
1/6 
2/6 
0/6 
0/6 
- 
- 
a: Compounds were tested at 10mg/kg dose level, ip. 
b: Rotarod toxicity (number of animals exhibiting toxicity/number of animals tested). 
Values are expressed as Mean±SEM 
** Values are significantly different from normal control at P<0.01 
*** Values are significantly different from normal control at P<0.001 
 
 
CONCLUSION 
The present study has proved that the 
synthesized 5- substituted Phenyl-3-(Thio-
phen-2-yl)-4, 5-dihydro-1H-pyrazole-1-car-
bothioamides showed promising antide-
pressant action and can be potential candi-
dates for the management of depression. 
The substitution pattern of thiophene based 
pyrazoline derivatives were carefully se-
lected to confer the effect of substituent in 
the phenyl system. Thus electron donating 
groups to phenyl system such as methoxy, 
dimethyl amino, hydroxyl and electron 
withdrawing group such as chloro and nitro 
were chosen as substituents on the chemical 
structure of the target compounds. Preclini-
cal evaluation for the synthesized deriva-
tives evidence assurance of the drug-
likeness property. Moreover, it is extensive-
ly reported that the inhibition of MAO-A 
level in the brain could be used to treat de-
pression state. We hypothesised that the 
thiophene containing pyrazoline carbothio-
amides can efficiently knockout the MAO 
system in mice and have revealed that they 
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exhibit a typical reduction in immobility in 
the forced swim test by increasing the 
swimming behaviour. However, to establish 
the detailed mechanism of these candidates, 
molecular interaction studies are necessary, 
which is expected to be carried out sepa-
rately as an extension of the present study. 
Moreover all effective 5- substituted phe-
nyl-3-(thiophen-2-yl)-4, 5-dihydro-1H-py-
razole-1-carbothioamides did not show 
acute neurotoxicity in the rotarod screen. 
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